These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
152 related articles for article (PubMed ID: 20555125)
1. Preparation, purification and virus inactivation of intravenous immunoglobulin from human plasma. Aghaie A; Pourfatollah AA; Bathaie SZ; Moazzeni SM; Khorsand Mohammad Pour H; Banazadeh S Hum Antibodies; 2010; 19(1):1-6. PubMed ID: 20555125 [TBL] [Abstract][Full Text] [Related]
2. Purification of intravenous immunoglobulin G from human plasma--aspects of yield and virus safety. Buchacher A; Iberer G Biotechnol J; 2006 Feb; 1(2):148-63. PubMed ID: 16892245 [TBL] [Abstract][Full Text] [Related]
3. Human intravenous immunoglobulin preparation and virus inactivation by pasteurization and solvent detergent treatment. Chang CE; Eo HG; Lee YS; Chung SK; Shin JS; Lah YK; Park CW; Jung JT; Huh JW; Lee SM Prep Biochem Biotechnol; 2000 Aug; 30(3):177-97. PubMed ID: 10919559 [TBL] [Abstract][Full Text] [Related]
4. Viral safety characteristics of Flebogamma DIF, a new pasteurized, solvent-detergent treated and Planova 20 nm nanofiltered intravenous immunoglobulin. Caballero S; Nieto S; Gajardo R; Jorquera JI Biologicals; 2010 Jul; 38(4):486-93. PubMed ID: 20350815 [TBL] [Abstract][Full Text] [Related]
5. Inactivation of virus in intravenous immunoglobulin G using solvent/detergent treatment and pasteurization. Aghaie A; Pourfatollah AA; Bathaie SZ; Moazzeni SM; Khorsand Mohammad Pour H; Sharifi Z Hum Antibodies; 2008; 17(3-4):79-84. PubMed ID: 19029665 [TBL] [Abstract][Full Text] [Related]
6. Virus reduction in an intravenous immunoglobulin by solvent/detergent treatment, ion-exchange chromatography and terminal low pH incubation. Roberts PL; Dunkerley C; Walker C Biologicals; 2012 Sep; 40(5):345-52. PubMed ID: 22658506 [TBL] [Abstract][Full Text] [Related]
7. [Inactivation of BVDV (experimental model for hepatitis C) using low pH and heat treatment in intravenous human immunoglobulins]. Ruibal Brunet IJ; Noa Romero E; Rivero Mas AT; Martín García RZ Sangre (Barc); 1999 Oct; 44(5):352-6. PubMed ID: 10618912 [TBL] [Abstract][Full Text] [Related]
8. Investigations of prion and virus safety of a new liquid IVIG product. Stucki M; Boschetti N; Schäfer W; Hostettler T; Käsermann F; Nowak T; Gröner A; Kempf C Biologicals; 2008 Jul; 36(4):239-47. PubMed ID: 18337119 [TBL] [Abstract][Full Text] [Related]
9. [Technology of immunoglobulin production. I. Technological aspects of purification]. Volkov GL Ukr Biokhim Zh (1999); 2006; 78(3):88-98. PubMed ID: 17100315 [TBL] [Abstract][Full Text] [Related]
10. Virus reduction in the preparation of intravenous immune globulin: in vitro experiments. Chandra S; Cavanaugh JE; Lin CM; Pierre-Jerome C; Yerram N; Weeks R; Flanigan E; Feldman F Transfusion; 1999 Mar; 39(3):249-57. PubMed ID: 10204586 [TBL] [Abstract][Full Text] [Related]
11. Inactivation of Zika virus by solvent/detergent treatment of human plasma and other plasma-derived products and pasteurization of human serum albumin. Kühnel D; Müller S; Pichotta A; Radomski KU; Volk A; Schmidt T Transfusion; 2017 Mar; 57(3pt2):802-810. PubMed ID: 28019034 [TBL] [Abstract][Full Text] [Related]
12. Enveloped virus inactivation by caprylate: a robust alternative to solvent-detergent treatment in plasma derived intermediates. Korneyeva M; Hotta J; Lebing W; Rosenthal RS; Franks L; Petteway SR Biologicals; 2002 Jun; 30(2):153-62. PubMed ID: 12127317 [TBL] [Abstract][Full Text] [Related]
13. Gamma irradiation of intravenous immunoglobulin. Drohan WN; Miekka SI; Griko YV; Forng RY; Stafford RE; Hill CR; Mann DM; Burgess WH Dev Biol (Basel); 2004; 118():133-8. PubMed ID: 15645683 [TBL] [Abstract][Full Text] [Related]
14. Viral safety of Nanogam, a new 15 nm-filtered liquid immunoglobulin product. Terpstra FG; Parkkinen J; Tölö H; Koenderman AH; Ter Hart HG; von Bonsdorff L; Törmä E; van Engelenburg FA Vox Sang; 2006 Jan; 90(1):21-32. PubMed ID: 16359352 [TBL] [Abstract][Full Text] [Related]
15. Comparative removal of solvent and detergent viral inactivating agents from human intravenous immunoglobulin G preparations using SDR HyperD and C18 sorbents. Burnouf T; Sayed MA; Radosevich M; El-Ekiaby M Anal Biochem; 2009 Jun; 389(1):69-73. PubMed ID: 19303391 [TBL] [Abstract][Full Text] [Related]
16. Pathogen safety of human C1 esterase inhibitor concentrate. Gröner A; Nowak T; Schäfer W Transfusion; 2012 Oct; 52(10):2104-12. PubMed ID: 22413956 [TBL] [Abstract][Full Text] [Related]
17. Physico-chemical and biological properties of solvent/detergent treated immunoglobuin G preparations. Nesterova NV; Kurkina OV; Samoilenko VA; Skrynnyk MM Mikrobiol Z; 2009; 71(6):35-42. PubMed ID: 20455431 [TBL] [Abstract][Full Text] [Related]
18. Structural study on immunoglobulin G solution after pasteurization with and without stabilizer. Aghaie A; Pourfathollah AA; Bathaie SZ; Moazzeni SM; Pour HK; Banazadeh S Transfus Med; 2008 Feb; 18(1):62-70. PubMed ID: 18279194 [TBL] [Abstract][Full Text] [Related]
19. Intravenous immunoglobulin G: trends in production methods, quality control and quality assurance. Radosevich M; Burnouf T Vox Sang; 2010 Jan; 98(1):12-28. PubMed ID: 19660029 [TBL] [Abstract][Full Text] [Related]